SOLAI Limited (NYSE:SLAI) experienced a 3.8% uptick in its after-hours trading session on Friday following disclosure that the New York Stock Exchange had issued a notice of non-compliance tied to the companys ADS share price.
The company said on January 29, 2026 that it had been informed by the NYSE that the average closing price of its American Depositary Shares fell below the $1.00 threshold over a consecutive 30 trading-day period as of January 28, 2026. That shortfall triggered the exchanges formal notification process under its continued listing standards.
Under NYSE rules, SOLAI has a six-month cure period from the date it received the notice to restore compliance with the minimum share price standard. The exchanges guidance allows the company to regain compliance if its ADSs close at a price of at least $1.00 on the last trading day of any calendar month during the cure period, and if the 30 consecutive trading-day average ending on that months last trading day is at least $1.00.
The notice does not cause any immediate change to the companys listing. SOLAIs ADSs will remain listed and tradable on the NYSE, subject to adherence to the exchanges other continued listing standards. The company stated that it currently meets those other standards.
Alongside the regulatory notice, SOLAI disclosed changes to its board of directors. Independent director Qian Sun resigned for personal reasons, with the resignation effective immediately. The company named Zhan Chen as an independent director. Chen will serve on the audit committee, the nominating and corporate governance committee, and the strategy committee.
The filings describe Chen as the founder and chief executive officer of Open Mouth Food Inc. He previously served as CEO of Boba Labs Inc. from 2022 to 2024. In a company statement, Bo Yu, Chairman of the Board and Chief Operating Officer, expressed gratitude to Sun for his service dating back to 2013 and welcomed Chen to the board.
Investors and market participants will watch the price action of SOLAIs ADSs over the coming months to see whether the shares can meet the NYSEs $1.00 average closing price requirement before the cure period expires. For now, trading continues uninterrupted and the company reports compliance with the exchanges other listing criteria.